• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    GE HealthCare debuts AI-supported solution, designed to improve and shorten the radiation therapy workflow, at ASTRO 2025

    9/25/25 9:00:00 AM ET
    $GEHC
    Medical Electronics
    Health Care
    Get the next $GEHC alert in real time by email
    • Early adopters of Intelligent Radiation Therapy (iRT) to date have reduced simulation to treatment planning time from seven days to seven minutes1 via integration with RayStation® by RaySearch Laboratories
    • The new version of iRT enhances connectivity, uses insights to improve efficiency, and includes a solution to manage workflows for the emerging field of theranostics
    • GE HealthCare will spotlight its comprehensive radiation oncology portfolio at its booth, underscoring the company's commitment to accelerating global access to radiation therapy

    GE HealthCare (NASDAQ: GEHC) today announced updates to Intelligent Radiation Therapy (iRT), a new version of the company's software solution for radiation therapy workflow management, designed to reduce the time it takes for patients to go from diagnosis to treatment. The iRT solution is AI-supported by GE HealthCare and third-party applications, and the latest features bring enhanced connectivity to the systems radiation oncology departments use most and use insights to improve departmental efficiency. The company also unveiled a new capability for theranostics that manages these complex workflows throughout the patient treatment journey, extending its expertise in radiation therapy workflows to this evolving field. The latest updates will be showcased at the American Society for Radiation Oncology (ASTRO) 2025 Annual Meeting in San Francisco for the first time.

    iRT seeks to improve workflow efficiencies

    Radiation therapy is a treatment nearly 60% of cancer patients2 receive, yet it can take up to 30 days3 just to begin. Radiation oncology workflows are complex, and teams work across many systems, but these systems rarely connect, contributing to possible treatment delays and errors. As a result, staff often re-enter the same data in multiple places, wasting time and increasing the risk of errors. Simple tasks, like importing treatment data, can take up to 17 manual steps. These inefficiencies can lead to potential inaccuracies that result in delayed treatments for patients and potentially poor outcomes.4 Today, hospitals worldwide are adopting iRT's vendor-neutral solution that manages data between systems to streamline the complex radiation therapy workflow, designed to enable a shorter timeline to treatment for patients and reduce workload for clinicians. Early adopters of iRT to date have seen the time reduced from seven days to seven minutes5 to go from simulation to treatment planning with integration of iRT and RayStation by RaySearch Laboratories. iRT delivers new features including:

    • Analytics reporting: gives department administrators a holistic view to analyze efficiency, identify operational gaps, and document trends.
    • Staff scheduler: accounts for out of office schedules using an intelligent resource management tool to optimize staffing, helping to reduce treatment delays.
    • Auto-segmentation of organs at risk by MR Contour DL6: uses AI to outline sensitive organs near the tumor so they can be protected during treatment, a process that was previously entirely manual. iRT has enabled connection with a GE HealthCare developed AI-model, MR Contour DL, for MR imaging and is interoperable with third-party devices MVision Contour+ for CT imaging, in addition to current interaction with MIM Contour ProtégéAI+™.
    • VERT virtual reality app from Vertual Ltd: connects to a third-party application that allows clinicians to walk patients through a simulation of the treatment process, helping reduce the fear of the unknown, and uses advanced 3D models to enhance staff training.
    • Greater connectivity: integrates with the systems radiation oncology departments use most, with a vendor-neutral approach, including electronic medical records (EMR), oncology information systems (OIS), and other fast healthcare interoperability resources (FHIR).

    "We are transforming the radiation therapy experience for patients and clinicians with our Intelligent Radiation Therapy solution, helping clinicians move from diagnosis to treatment in minutes, not days," says Ben Newton, GE HealthCare's general manager for Oncology Solutions. "We're thrilled to share the latest features in iRT designed to bring greater precision, efficiency, and personalization to cancer care."

    Introduction of iRT for theranostics

    Theranostics is a branch of nuclear medicine that uses molecular imaging and targeted radionuclide therapies aimed at the same biological target to treat cancer in the body and is gaining interest for advanced-stage cancer outcomes. These therapeutic and diagnostic technologies work together to enable a personalized, highly precise, patient-centric approach to medical diagnosis and treatment. Today, many steps of the workflow are manual, which is further complicated by the significant communication and triage needed to facilitate a patient's treatment plan, leading to wasted doses of medication or delayed treatments.7

    The iRT features for theranostics aim to bring a unified view to this highly complex treatment. It integrates with EMRs and OIS to give a holistic view of the patient journey and guide clinicians step-by-step through patient intake, patient assessment, scheduling, medication dosing, dosimetry, and clinical reviews.

    "Miami Cancer Institute is pleased to collaborate with GE HealthCare on iRT, an innovative solution designed to address the rapidly evolving landscape of radiopharmaceuticals," said Dr. Ranjini Tolakanahalli, director of photon physics at Miami Cancer Institute, part of Baptist Health South Florida. "Together, we are developing a solution where clinical priorities shape design, ensuring future solutions are informed by real-world medical expertise."

    Full suite of radiation oncology solutions on showcase at ASTRO 2025

    GE HealthCare will also showcase the latest versions of the following radiation oncology solutions aimed at improving radiation oncology outcomes for patients at ASTRO 2025:

    • MIM Maestro: Now with a reirradiation and composite plan assessment workflow, MIM Maestro empowers clinicians to make confident treatment decisions in scenarios where clinicians are evaluating multiple past treatments. Clinicians can visualize any number of prior external beam radiation therapy (EBRT) plan doses on current anatomy and account for radiobiological effects—all within a single, flexible workflow. Using rigid or deformable image registration, dose is accurately adjusted per structure, while iterative planning enables comparison of multiple treatment options and comprehensive dose visualization for EBRT plans from any vendor.
    • iRT MR Direct Solution: The iRT advanced AI solution enables MRI-only RT Planning for Brain/Head and Neck/Pelvis. iRT MR Direct complements GE HealthCare's proven AIR RT Suite MR-simulation solution and is designed to help clinicians within each workflow step, from positioning to contouring and simulation for RT planning. iRT MR Direct includes:
      • MR Contour DL: An AI-enabled application that automatically contours organs-at-risk (OAR) for head and neck and pelvis on MR images.
      • MRI Planner: An AI-enabled technology from Spectronic Medical that generates synthetic CT images from MR images for dose calculation.

    Additionally, GE HealthCare is hosting a lunch symposium, "Converging beams: Radiation therapy meets radioligand therapy," on Sept. 28 at 12:00 p.m. PT. This expert panel will explore the underlying biological rationale and emerging clinical evidence, while also delving into real-world implementation strategies for combining these modalities across diverse oncology program settings.

    To learn more about GE HealthCare's oncology care solutions, please visit booths #225 and #325 at the Moscone Center in San Francisco, CA from Sept. 28 – Oct. 1 or visit this ASTRO event page.

    About GE HealthCare Technologies Inc.

    GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for more than 125 years, GE HealthCare is advancing personalized, connected and compassionate care, while simplifying the patient's journey across care pathways. Together, our Imaging, Advanced Visualization Solutions, Patient Care Solutions and Pharmaceutical Diagnostics businesses help improve patient care from screening and diagnosis to therapy and monitoring. We are a $19.7 billion business with approximately 53,000 colleagues working to create a world where healthcare has no limits.

    GE HealthCare is proud to be among 2025 Fortune World's Most Admired Companies™.

    Follow us on LinkedIn, X, Facebook, Instagram, and Insights for the latest news, or visit our website https://www.gehealthcare.com for more information.

    ____________________________________

    1 Based on two InstaPlan (iRT + RayStation by RaySearch) clinical studies in Europe based on a total of 20 patients. Any results achieved using InstaPlan may vary based on differences in workflows, patient populations or other factors.

    2 American Society for Radiation Oncology. Radiation Oncology Case Rate (ROCR) Report. June 26, 2023. https://www.astro.org/ASTRO/media/ASTRO/Advocacy/PDFs/ROCRReport.pdf.

    3 https://research.gehealthcare.com/across-the-enterprise/4-benefits-of-open-architecture-jb34091xx-in-intelligent-radiation-therapy-irt/

    4 Gopan, Olga, Jing Zeng, Avrey Novak, Matthew Nyflot, and Eric Ford. 2016. "The Effectiveness of Pretreatment Physics Plan Review for Detecting Errors in Radiation Therapy." Journal of Applied Clinical Medical Physics 17 (5): 16–31. https://doi.org/10.1118/1.4961010.[1](https://aapm.onlinelibrary.wiley.com/doi/pdf/10.1118/1.4961010)

    5 Based on two InstaPlan (iRT + RayStation by RaySearch) clinical studies in Europe based on a total of 20 patients. Any results achieved using InstaPlan may vary based on differences in workflows, patient populations or other factors.

    6 Not available in all regions.

    7 GE HealthCare internal data. Results may vary. The statements by GE HealthCare customers are based on their opinions and results achieved in their unique setting. Since many variables exist (i.e., size, case mix, etc.), there can be no guarantee that other customers will achieve the same results.

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250925074542/en/

    Media Contact

    Karin Dalsin

    Global Communications Director

    GE HealthCare

    +1 612-219-2855

    [email protected]

    Get the next $GEHC alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GEHC

    DatePrice TargetRatingAnalyst
    5/5/2025$73.00Sell → Neutral
    UBS
    3/11/2025$85.00 → $100.00Neutral → Buy
    Goldman
    1/8/2025$95.00 → $103.00Hold → Buy
    Jefferies
    9/26/2024$84.00 → $74.00Neutral → Sell
    UBS
    9/18/2024$100.00Neutral → Buy
    BTIG Research
    9/9/2024$90.00Neutral
    JP Morgan
    8/6/2024$100.00Buy
    Stifel
    5/30/2024$87.00Neutral
    Goldman
    More analyst ratings

    $GEHC
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Jimenez Frank R bought $100,624 worth of shares (1,315 units at $76.52), increasing direct ownership by 2% to 75,796 units (SEC Form 4)

    4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

    5/2/24 6:00:38 AM ET
    $GEHC
    Medical Electronics
    Health Care

    $GEHC
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    GE HealthCare debuts AI-supported solution, designed to improve and shorten the radiation therapy workflow, at ASTRO 2025

    Early adopters of Intelligent Radiation Therapy (iRT) to date have reduced simulation to treatment planning time from seven days to seven minutes1 via integration with RayStation® by RaySearch Laboratories The new version of iRT enhances connectivity, uses insights to improve efficiency, and includes a solution to manage workflows for the emerging field of theranostics GE HealthCare will spotlight its comprehensive radiation oncology portfolio at its booth, underscoring the company's commitment to accelerating global access to radiation therapy GE HealthCare (NASDAQ: GEHC) today announced updates to Intelligent Radiation Therapy (iRT), a new version of the company's software solut

    9/25/25 9:00:00 AM ET
    $GEHC
    Medical Electronics
    Health Care

    GE HealthCare announces cash dividend for third quarter of 2025

    The Board of Directors of GE HealthCare Technologies Inc. (NASDAQ:GEHC) today declared a cash dividend of $0.035 per share of Common Stock for the third quarter of 2025 payable on November 14, 2025 to all shareholders of record as of October 24, 2025. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for

    9/24/25 3:58:00 PM ET
    $GEHC
    Medical Electronics
    Health Care

    Lantheus and GE HealthCare Announce Exclusive Licensing Agreement for Prostate Cancer Imaging Agent PYLARIFY® (Piflufolastat F 18) in Japan

    BEDFORD, Mass. and CHICAGO and TOKYO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc.  (NASDAQ:LNTH) and GE HealthCare (NASDAQ:GEHC) today announced an exclusive licensing agreement for GE HealthCare to develop, manufacture, and commercialize Lantheus' piflufolastat F18 (PYLARIFY® in U.S. market) in Japan for prostate cancer diagnostics and companion diagnostic use. PYLARIFY is used for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer. The agreement includes the transfer of regulatory dossiers, manufacturing competencies and technical support to enable GE HealthCare to drive clinical development

    9/24/25 1:00:00 AM ET
    $GEHC
    $LNTH
    Medical Electronics
    Health Care
    Biotechnology: In Vitro & In Vivo Diagnostic Substances

    $GEHC
    SEC Filings

    View All

    SEC Form 144 filed by GE HealthCare Technologies Inc.

    144 - GE HealthCare Technologies Inc. (0001932393) (Subject)

    9/22/25 4:44:03 PM ET
    $GEHC
    Medical Electronics
    Health Care

    SEC Form 144 filed by GE HealthCare Technologies Inc.

    144 - GE HealthCare Technologies Inc. (0001932393) (Subject)

    9/12/25 4:47:37 PM ET
    $GEHC
    Medical Electronics
    Health Care

    SEC Form SCHEDULE 13G filed by GE HealthCare Technologies Inc.

    SCHEDULE 13G - GE HealthCare Technologies Inc. (0001932393) (Subject)

    8/13/25 4:35:15 PM ET
    $GEHC
    Medical Electronics
    Health Care

    $GEHC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    GE HealthCare upgraded by UBS with a new price target

    UBS upgraded GE HealthCare from Sell to Neutral and set a new price target of $73.00

    5/5/25 8:34:55 AM ET
    $GEHC
    Medical Electronics
    Health Care

    GE HealthCare upgraded by Goldman with a new price target

    Goldman upgraded GE HealthCare from Neutral to Buy and set a new price target of $100.00 from $85.00 previously

    3/11/25 7:35:30 AM ET
    $GEHC
    Medical Electronics
    Health Care

    GE HealthCare upgraded by Jefferies with a new price target

    Jefferies upgraded GE HealthCare from Hold to Buy and set a new price target of $103.00 from $95.00 previously

    1/8/25 7:50:38 AM ET
    $GEHC
    Medical Electronics
    Health Care

    $GEHC
    Financials

    Live finance-specific insights

    View All

    GE HealthCare announces cash dividend for third quarter of 2025

    The Board of Directors of GE HealthCare Technologies Inc. (NASDAQ:GEHC) today declared a cash dividend of $0.035 per share of Common Stock for the third quarter of 2025 payable on November 14, 2025 to all shareholders of record as of October 24, 2025. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services and data analytics. We aim to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier. Serving patients and providers for

    9/24/25 3:58:00 PM ET
    $GEHC
    Medical Electronics
    Health Care

    GE HealthCare reports second quarter 2025 financial results

    Revenue growth was 3% year-over-year; Organic revenue growth* was 2% Net income margin was 9.7% versus 8.9% for the prior year; Adjusted earnings before interest and taxes (EBIT) margin* was 14.6% versus 15.3% Diluted earnings per share (EPS) were $1.06 versus $0.93 for the prior year; Adjusted EPS* was $1.06 versus $1.00 Cash flow from operating activities was $94 million versus $(119) million for the prior year; Free cash flow* was $7 million versus $(182) million Raises full-year 2025 guidance GE HealthCare (NASDAQ:GEHC) today reported financial results for the second quarter ended June 30, 2025. GE HealthCare President and CEO Peter Arduini said, "We were pleas

    7/30/25 6:20:00 AM ET
    $GEHC
    Medical Electronics
    Health Care

    GE HealthCare to announce second quarter 2025 results on July 30, 2025

    GE HealthCare (NASDAQ:GEHC) will announce its second quarter 2025 financial results before the market opens on Wednesday, July 30, 2025. The GE HealthCare management team will also host a conference call and webcast at 8:30 a.m. Eastern Time / 7:30 a.m. Central Time on that same day, which will be a live webcast and accessible at https://investor.gehealthcare.com/news-events/events. The earnings release, accompanying financial information, and webcast replay also will be posted at the same link on the GE HealthCare Investor Relations website. About GE HealthCare Technologies Inc. GE HealthCare is a trusted partner and leading global healthcare solutions provider, innovating medical techno

    7/7/25 8:00:00 AM ET
    $GEHC
    Medical Electronics
    Health Care

    $GEHC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO, Imaging Rott Roland covered exercise/tax liability with 4,620 shares and exercised 5,341 shares at a strike of $55.91, increasing direct ownership by 3% to 29,122 units (SEC Form 4)

    4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

    9/12/25 4:05:10 PM ET
    $GEHC
    Medical Electronics
    Health Care

    Chief Enterprise Oper. Officer Stacherski Kenneth R. covered exercise/tax liability with 892 shares, decreasing direct ownership by 2% to 40,996 units (SEC Form 4)

    4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

    9/3/25 4:19:36 PM ET
    $GEHC
    Medical Electronics
    Health Care

    Chief People Officer Holton Adam Y covered exercise/tax liability with 464 shares, decreasing direct ownership by 3% to 16,768 units (SEC Form 4)

    4 - GE HealthCare Technologies Inc. (0001932393) (Issuer)

    9/3/25 4:18:39 PM ET
    $GEHC
    Medical Electronics
    Health Care

    $GEHC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by GE HealthCare Technologies Inc.

    SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

    11/12/24 12:53:28 PM ET
    $GEHC
    Medical Electronics
    Health Care

    Amendment: SEC Form SC 13G/A filed by GE HealthCare Technologies Inc.

    SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

    10/22/24 4:16:16 PM ET
    $GEHC
    Medical Electronics
    Health Care

    SEC Form SC 13G/A filed by GE HealthCare Technologies Inc. (Amendment)

    SC 13G/A - GE HealthCare Technologies Inc. (0001932393) (Subject)

    4/2/24 4:07:29 PM ET
    $GEHC
    Medical Electronics
    Health Care

    $GEHC
    Leadership Updates

    Live Leadership Updates

    View All

    PharmaLogic Announces Appointment of Etienne Montagut as President and Chief Executive Officer

    BOCA RATON, Fla., June 2, 2025 /PRNewswire/ -- PharmaLogic Holdings Corp. ("PharmaLogic" or "the Company"), a leading contract development and manufacturing organization (CDMO) specialized in radiopharmaceuticals, today announces the Company has appointed Etienne Montagut, currently serving as President, to the position of President and Chief Executive Officer, effective as of 1 June 2025. Mr. Montagut brings over 25 years of senior leadership experience in the pharmaceutical sector, with a solid track record of driving growth and executing strategic transformation across glob

    6/2/25 8:00:00 AM ET
    $GEHC
    $LNTH
    Medical Electronics
    Health Care
    Biotechnology: In Vitro & In Vivo Diagnostic Substances

    GE HealthCare names Jeannette Bankes president and CEO, Patient Care Solutions

    GE HealthCare (NASDAQ:GEHC), a leading global healthcare solutions provider, announced the appointment of Jeannette Bankes as president and CEO, Patient Care Solutions, effective May 1, 2025. Peter Arduini, president and CEO, GE HealthCare, said, "Jeannette is a proven leader who has diverse and deep experience at publicly traded companies in the healthcare industry. We proudly welcome her to the company and are confident that she has the expertise to move Patient Care Solutions forward and deliver on our precision care strategy." Bankes brings with her three decades of global experience including product management, marketing, sales, regulatory, medical affairs, and operations and manufa

    4/9/25 9:00:00 AM ET
    $GEHC
    Medical Electronics
    Health Care

    GE HealthCare's MIM Software collaborates with Elekta to help enhance radiation therapy treatments and improve patient outcomes

    Collaboration has always been important in the healthcare industry, but in this era of digital health, teamwork across institutions has become essential Enhancing Elekta's radiation therapy offerings with GE HealthCare's MIM Software medical imaging management solutions will help drive greater benefits for global healthcare systems This new collaboration complements GE HealthCare and Elekta's existing global commercial collaboration agreement, which enables the two companies to provide hospitals and cancer patients a comprehensive radiation therapy offering across imaging and treatment Weeks after closing its acquisition of MIM Software – a global provider of medical imaging analy

    4/22/24 7:07:00 AM ET
    $GEHC
    Medical Electronics
    Health Care